Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Aug 20:6:8-14.
doi: 10.1016/j.jcte.2016.08.002. eCollection 2016 Dec.

Lipid disorders in patients with renal failure: Role in cardiovascular events and progression of chronic kidney disease

Luca Visconti  1 , Salvatore Benvenga  2 , Antonio Lacquaniti  1 , Valeria Cernaro  1 , Annamaria Bruzzese  1 , Giovanni Conti  3 , Michele Buemi  1 , Domenico Santoro  1
Affiliations
Review

Lipid disorders in patients with renal failure: Role in cardiovascular events and progression of chronic kidney disease

Luca Visconti et al. J Clin Transl Endocrinol. .

Abstract

The spectrum of lipid disorders in chronic kidney disease (CKD) is usually characterized by high triglycerides and reduced high dense lipoprotein (HDL), associated with normal or slightly reduced low dense lipoprotein (LDL)-cholesterol. This dyslipidemia is associated with an increased risk for atherosclerotic cardiovascular disease. Keys for the cardiovascular risk reduction in these patients are lowering the number and modifying the composition of the cholesterol-carrying atherogenic lipoprotein particles. Statins have an important role in primary prevention of cardiovascular events and mortality in non-hemodialyzed CKD patients. The benefits in terms of progression of renal failure are contradictory. Patient education regarding dietary regimen should be part of the CKD clinical management.

Keywords: Cardiovascular events; Chronic kidney disease; Diet; Lipids; Proteinuria; Statin.

PubMed Disclaimer

References

    1. Lacquaniti A., Bolignano D., Donato V., Bono C., Fazio M.R., Buemi M. Alterations of lipid metabolism in chronic nephropathies: mechanisms, diagnosis and treatment. Kidney Blood Press Res. 2010;33:100–110. - PubMed
    1. Endo A. A historical perspective on the discovery of statins. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86:484–493. - PMC - PubMed
    1. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–1847. - PubMed
    1. Stamler J., Wentworth D., Neaton J.D. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT) JAMA. 1986;256:2823–2828. - PubMed
    1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet. 1994;344:1383–1389. - PubMed